iiinova — where your digital self keeps evolving

Vincent Rajkumar, MD

@vincentrk.bsky.social

6.5K followers 13 following 13 posts

Editor in Chief, Blood Cancer Journal; Professor, Mayo Clinic; Associate Editor, Mayo Clinic Proceedings; Oncologist, Cancer Research, Myeloma.

Posts Replies Media

Vincent Rajkumar, MD @vincentrk.bsky.social · 18/10/2025

Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...

0143

Reposted by Vincent Rajkumar, MD

Megan Weivoda, Ph.D. @megvoda.bsky.social · 09/12/2024

So excited to see this thread on BlueSky, @vincentrk.bsky.social! Thank you as always for your excellent summaries!

1101

Vincent Rajkumar, MD @vincentrk.bsky.social · 22/12/2024

Wow. I’m overwhelmed by the response here. Will post more on here.

2220

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

It is through clinical trials that new treatments are discovered, tested, and approved. A medicine is a chemical and will stay so in the absence of clinical trials. No trial, no medicines. I’m thankful for colleagues who run clinical trials. #ASH24

0180

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

9. All the active drugs for myeloma in one simple table. Black font = approved drugs; blue font = investigational.

1151

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

8. Will post hot-of-the-press smoldering myeloma SMM treatment algorithm Monday afternoon #ASH24 AQUILA trial! Stay tuned.

130

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

7. For more details check out my 2024 Annual myeloma diagnosis and treatment update published in Am J Hematology. #OpenAccess #ASH24 onlinelibrary.wiley.com/doi/10.1002/...

onlinelibrary.wiley.com

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management

Disease overview Multiple myeloma accounts for approximately 10% of hematologic malignancies. Diagnosis The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma ...

130

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

6. In general if possible and available a clinical trial is preferable to these algorithms. These are general principles. You have to individualize treatment selection. Also treatments evolve. Follow msmart.org for updates @MayoMyeloma #ASH24

msmart.org

mSMART

110

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

5. True Penta-Refractory myeloma (refractory to PI, Imid, CD38, alkylator, and BCMA targeted approach). msmart.org #ASH24

120

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

4. Second or later relapse mSMART.org #ASH24

120

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

3) First Relapse I don’t recommend CART in first relapse even though it’s approved except in very selected patients (eg., high risk progressing early while on quad). msmart.org #ASH24

120

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

2. Newly diagnosed transplant eligible. Quadruplet induction. See below for transplant timing and maintenance. #ASH24

120

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

1336

Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024

My first post here. Holy cow! And I already have followers here! Thanks so much everyone. I’m still trying to figure out how to post on X and here. #ASH24

6360